Continuous Glucose Monitoring (CGM) represents one of the most significant technological advancements in diabetes care since the discovery of insulin. Unlike traditional Self-Monitoring of Blood Glucose (fingersticks), which provide single-point-in-time measurements, CGM systems offer a continuous, real-time dynamic view of glucose levels. Clinically, CGMs measure interstitial glucose (the concentration of glucose in the fluid between cells) using a tiny sensor inserted subcutaneously. The sensor contains enzymes, typically glucose oxidase, that react with glucose to generate a tiny electrical current, which is then translated into glucose concentration readings and sent to a reader or smartphone app.
Types of CGM Systems: rtCGM vs. isCGM
CGM devices generally fall into two categories: real-time CGM (rtCGM) and intermittently scanned CGM (isCGM, also known as flash CGM). Real-time CGM systems automatically transmit glucose data to a receiver or smartphone app every few minutes and are equipped with programmable alerts for low and high glucose levels. Intermittently scanned CGM systems require the user to actively scan the sensor with a reader or smartphone to retrieve the glucose data. Both types offer valuable retrospective analysis, but rtCGM is often preferred for patients at high risk of hypoglycemia due to its active alert systems.
One critical clinical concept is the physiological lag time. Because CGM measures interstitial glucose rather than capillary blood glucose, there is a delay of 5 to 15 minutes for glucose to diffuse from the bloodstream into the interstitial space. During times of stable glucose, interstitial and blood glucose levels are nearly identical. However, during rapid changes—such as immediately after a high-carb meal, during intensive exercise, or during rapid drops in blood sugar—the CGM reading may lag behind the actual blood glucose level. Therefore, confirmation with a fingerstick is always recommended before executing treatment decisions for suspected hypoglycemia or when symptoms do not match CGM readings.
💡 💡 The Lag Time Phenomenon
CGM devices measure glucose in the interstitial fluid (the fluid between cells), not the blood. Because of this, there is a physiological lag time of 5 to 15 minutes. During rapid glucose changes (e.g., after eating or during exercise), always confirm your readings with a fingerstick before making treatment decisions.
Key Metrics and CGM Data Interpretation
CGM data has shifted the clinical paradigm from relying solely on HbA1c to analyzing detailed glycemic patterns. As outlined in the International Consensus on Time in Range (TIR), key metrics include:
- Time in Range (TIR): The percentage of time glucose is between 70 and 180 mg/dL (3.9 to 10.0 mmol/L). The target for most adults is greater than 70 percent, which corresponds to an HbA1c of approximately 7.0 percent.
- Time Below Range (TBR): The percentage of time glucose is below 70 mg/dL (Level 1) or below 54 mg/dL (Level 2). The clinical target is less than 4 percent at Level 1 and less than 1 percent at Level 2 to minimize dangerous hypoglycemia.
- Time Above Range (TAR): The percentage of time glucose is above 180 mg/dL (Level 1) or above 250 mg/dL (Level 2). The goal is to minimize this to prevent chronic microvascular damage.
- Glycemic Variability: Measured by the Coefficient of Variation (CV), with a target of 36 percent or less to indicate stable glucose patterns. High glycemic variability is associated with an increased risk of hypoglycemia and oxidative stress.
Clinical Benefits and Evidence
Large-scale clinical trials have validated the benefits of CGM. The DIAMOND randomized clinical trial demonstrated that adults with type 1 diabetes using multiple daily insulin injections achieved a significant reduction in HbA1c and decreased hypoglycemia exposure when using rtCGM compared to fingersticks. Similarly, studies in type 2 diabetes show that CGM use improves self-management by providing immediate visual feedback on the glycemic effects of specific foods and physical activities, leading to sustained lifestyle modifications and improved metabolic health.
Practical Care and Wearer Tips
Applying and maintaining a CGM sensor requires attention to detail. Sensor site selection (typically the back of the upper arm or the abdomen) should avoid scars, tattoos, or areas prone to bending. Proper skin preparation—washing with soap, drying completely, and using adhesive barrier wipes if necessary—helps prevent premature sensor detachment. Additionally, users should be aware of “compression lows.” These are false low readings that occur when pressure is applied directly to the sensor (for instance, when sleeping on it), causing local blood flow restriction and a transient artificial drop in interstitial glucose. If a low alert wakes a patient but they feel normal, they should check their capillary glucose before consuming fast-acting sugars.
💡 Frequently Asked Questions (FAQ)
Q1: Do I still need to perform fingersticks if I have a CGM?
A1: Yes, occasionally. Fingersticks are required to calibrate the sensor (if specified by the manufacturer), to confirm a low glucose alert, and to make treatment decisions if your symptoms do not match the CGM reading or if the device displays a sensor error.
Q2: Can I swim or bathe with my CGM sensor?
A2: Yes. CGM sensors and transmitters are designed to be water-resistant. Most can be submerged in water up to a certain depth (usually 3 to 8 feet) for up to 30 minutes. However, prolonged exposure to hot water (like hot tubs) may weaken the adhesive or damage the electronics.
Q3: What is the Glucose Management Indicator (GMI)?
A3: The GMI is an estimate of your HbA1c based on your average glucose levels captured by the CGM over a period of at least 12 to 14 days. While it correlates closely with laboratory HbA1c, it can differ slightly due to individual variations in red blood cell lifespan.
📚 References & Sources
- Battelino, T., et al. (2019). Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care, 42(8), 1593-1603.
- Beck, R. W., et al. (2017). Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA, 317(4), 371-378.